Press releases

Phase II of the antibiotic candidate DNV3837 ongoing – end of the first part of the trial (DSMB) expected in Q4 2021 Strengthening of...

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to...

This new agreement with European Select Growth Opportunities Fund enables the issuance of notes convertible into new shares for a maximum...

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to...

DEINOVE is intensifying its collaboration with the Max Mousseron Institute of Biomolecules (IBMM) and the Physical Measurement Laboratory (...

The Extraordinary Shareholders’ Meeting will be convened on third notice at a later date DEINOVE (Euronext Growth Paris: ALDEI), a French...

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to...

The Microflu4AMR project, based on microfluidic technology and the exploitation of soil microbial diversity, will enable the search and...

Phase II of the antibiotic candidate DNV3837 ongoing – end of the first part of the trial (DSMB) expected mid-2021 Signature of an...

DEINOVE’s Boost-ID project has been selected as part of the “France Relance” plan, a recognition of its strategic positioning. Boost-ID is...